The abstracts for the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, released earlier this month, indicate that the main areas of interest in myeloma this year focus on novel treatment combinations including daratumumab (Darzalex®), other anti-CD38 antibodies, checkpoint inhibitors, pomalidomide (Imnovid®), carfilzomib (Kyprolis®) and venetoclax. In total, 84 abstracts on myeloma and related conditions will be presented with 10 in the oral sessions. Other presentations include results from:

  • EMN02/HOVON95 trial for transplant-eligible patients evaluating the role of minimal residual disease (MRD) testing
  • Denosumab versus zoledronic acid head-to-head trial showing that denosumab is associated with lower renal-related side effects
  • Analysis of cardiovascular side-effects associated with carfilzomib
  • Myeloma XI trial investigating the benefits of lenalidomide (Revlimid®) induction and maintenance treatment in the transplant setting
  • Retrospective analysis investigating the outcomes of patients with t(11;14) cytogenetics

Abstracts can be viewed here